% | $
Quotes you view appear here for quick access.

Sunesis Pharmaceuticals, Inc. Message Board

  • tintinbong tintinbong Sep 10, 2012 10:22 PM Flag

    opens at 60 cents after the failure news is announced, they have no other drug

    in pipeline, none of them even phase 1
    and you idiots were gambling on this P&D fraud

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • you get the dumbazz award for today - better buy a new bong

    • "will loose everything when this gold bull #$%$ ends..

      The sad part is there are too many #$%$ in gold media who think POG heading for some 3000"

      You said this about 9 years ago. You clearly have a bias to the short side,

      your posts are not objective at all! You short and pray that the price goes down. If there was real news on SNSS that was negative, SNSS would have closed below 2(it would trade down 50%+). The question is where will the shorts cover @ $5 or above $10. My guess is they won't have a chance....the gap up will wipe out a fair share of these shorts.

    • SOUTH SAN FRANCISCO, Calif., June 27, 2012 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it has received a $1.5 million milestone payment from Biogen Idec (Nasdaq:BIIB) for the advancement of pre-clinical work under its 2011 amended and restated multi-kinase inhibitor collaboration agreement. Under the agreement, Sunesis is also eligible to receive up to $60 million in pre-commercial milestone program payments as well as royalties on sales of future collaboration products. Sunesis retains future co-development and co-promotion options to the program.

      "Our earlier-stage programs, which were divided into immunology and oncology following Millennium Pharmaceuticals' licensing of the oncology programs, are emerging as prominent assets for Sunesis," said Daniel Swisher, Chief Executive Officer of Sunesis. "Importantly, our kinase inhibitor collaborations allow us to leverage the resources of leading biopharmaceutical companies to advance our earlier stage pipeline, while we focus our resources on vosaroxin and the ongoing Phase 3 VALOR trial in AML."

2.85-0.09(-3.06%)Jun 29 4:00 PMEDT